Skip to main content
Top
Published in: Medical Oncology 4/2014

01-04-2014 | Letter to the Editor

Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer

Authors: Mingming Wang, Lin Shen, Dajun Deng

Published in: Medical Oncology | Issue 4/2014

Login to get access

Excerpt

Aberrant methylation of CHFR (Checkpoint with forkhead associated and ring finger) gene was frequently happened in cancer and had been reported to be associated with the sensitivity of microtubule inhibitors in several cancer cells containing gastric cancer cells in vitro experiments [1]. However, the clinical significance of CHFR methylation and chemosensitivity of microtubule inhibitors (paclitaxel or docetaxel) in gastric cancer patients was investigated only in few studies with limited samples, and the conclusion was controversial [2, 3]. In this study, we aimed to investigate the association between CHFR methylation and the sensitivity of paclitaxel in Chinese advanced gastric cancer (AGC) patients to identify the potential predictor of paclitaxel. …
Literature
1.
go back to reference Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2013. Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2013.
2.
go back to reference Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006;41(2):133–9.PubMedCrossRef Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol. 2006;41(2):133–9.PubMedCrossRef
3.
go back to reference Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, Yasui W. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res. 2006;26(1A):49–54.PubMed Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, Yasui W. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res. 2006;26(1A):49–54.PubMed
Metadata
Title
Association between CHFR methylation and chemosensitivity of paclitaxel in advanced gastric cancer
Authors
Mingming Wang
Lin Shen
Dajun Deng
Publication date
01-04-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0907-6

Other articles of this Issue 4/2014

Medical Oncology 4/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.